

Special Issue

Pharmacogenetics of Treating Anxiety & Depression

Message from the Guest Editor

Pharmacogenetics has the potential to improve the treatment of anxiety and depression. Though some institutions have been implementing pharmacogenetics in the clinical care of patients with anxiety and depression for many years, there is still much more research to be done. The aim of this Special Issue is to provide a comprehensive overview of how pharmacogenetics can influence the efficacy and tolerability of medications used to treat anxiety and depression, the current state of research in this area, and the challenges and opportunities for implementation in clinical care. Articles may be in the areas of discovery, replication, trial design, position papers, meta-analyses, or a description of your implementation. Articles may be in the form of research article, review paper, or communication.

Guest Editor

Dr. Laura B. Ramsey

1. Divisions of Clinical Pharmacology & Research in Patient Services, Cincinnati, OH 45229, USA
2. Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
3. College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA

Deadline for manuscript submissions

closed (31 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/76279

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).